SCHEMBL3750962

SCHEMBL3750962

FC(F)(F)COc1ccccc1-c1ccc2[nH]c(/C=C/C3CCCCC3)nc2c1

nearest known ligand 0.63

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 2/20 0.63
CYP2C9 P11712 2/20 0.63
TRPM8 Q7Z2W7 1/20 0.63
TRPV1 Q8NER1 11/20 0.41
ALOX5AP P20292 1/20 0.39
FEN1 P39748 1/20 0.39
SCN9A Q15858 3/20 0.39
SCN5A Q14524 1/20 0.37
ACP1 P24666 1/20 0.36
TRPA1 O75762 1/20 0.34
NPC1 O15118 1/20 0.33
CYP1A2 P05177 1/20 0.33
CYP2D6 P10635 1/20 0.33
CYP2C19 P33261 1/20 0.33
RAB9A P51151 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3750963 1.00 CYP3A4 (0.63) CYP3A4CYP2C9TRPM8TRPV1ALOX5AP
SCHEMBL3740551 0.87 CYP2C9 (0.63) CYP3A4CYP2C9TRPM8TRPV1SCN9A
SCHEMBL3740557 0.87 CYP2C9 (0.63) CYP3A4CYP2C9TRPM8TRPV1SCN9A
Hydrochloric Acid SCHEMBL2789872 0.87 CYP2C9 (0.62) CYP3A4CYP2C9TRPM8TRPV1SCN9A
Hydrochloric Acid SCHEMBL3750538 0.87 CYP2C9 (0.62) CYP3A4CYP2C9TRPM8TRPV1SCN9A
SCHEMBL3745835 0.86 CYP3A4 (0.62) CYP3A4CYP2C9TRPM8TRPV1SCN9A
SCHEMBL2770465 0.86 CYP3A4 (0.62) CYP3A4CYP2C9TRPM8TRPV1SCN9A
SCHEMBL2772149 0.85 CYP2C9 (0.85) CYP3A4CYP2C9TRPM8TRPV1TRPA1
SCHEMBL3744235 0.85 CYP2C9 (0.85) CYP3A4CYP2C9TRPM8TRPV1TRPA1
Hydrochloric Acid SCHEMBL2793643 0.84 CYP2C9 (0.83) CYP3A4CYP2C9TRPM8TRPV1TRPA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8217060-B2 Benzimidazole derivatives useful as TRP M8 receptor modulators JANSSEN PHARMACEUTICA, NV (BE) 2012-07-10 US claimed
US-20100292276-A1 BENZIMIDAZOLE DERIVATIVES USEFUL AS TRP M8 RECEPTOR MODULATORS JANSSEN PHARMACEUTICA, NV (BE) 2010-11-18 US claimed
US-8217060-B2 Benzimidazole derivatives useful as TRP M8 receptor modulators JANSSEN PHARMACEUTICA, NV (BE) 2012-07-10 US disclosed
US-20100292276-A1 BENZIMIDAZOLE DERIVATIVES USEFUL AS TRP M8 RECEPTOR MODULATORS JANSSEN PHARMACEUTICA, NV (BE) 2010-11-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100292276-A1 BENZIMIDAZOLE DERIVATIVES USEFUL AS TRP M8 RECEPTOR MODULATORS TRPM8, TRPV1, TRPA1 CYP3A4 2735/4885CYP2C9 2805/4885TRPM8 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.